

Reach2HD trial completed



Hypothesis

Huntington's disease is an uncommon inherited disorder characterized by a combination of motor, cognitive and psychiatric symptoms that evolve over many years. PBT2 targets either the aggregation of huntingtin or the direct toxicity of mutant huntingtin protein through its interactions with copper and/or zinc and the restoration of neuronal metal homeostasis.

Huntington's disease clinical trial update

Neurodegenerative Disorders Research Pty Ltd was involved in a six-month Huntington's disease clinical trial: Reach2HD, sponsored by Prana Biotechnology Limited.

The aim of the study was to assess the safety, tolerability and efficacy of two dose levels of PBT2 when administered orally once daily over 26 weeks in patients with early to mid-stage Huntington's disease.

Participants play an important role

The trial commenced in 2012 and the final subject visit was held on 24 June 2013.

Worldwide 109 subjects were recruited. Neurodegenerative Disorders Research Pty Ltd in Subiaco recruited 11 patients.

The trial ran smoothly at our site with no major complications.

All subjects who participated need to be congratulated.

In December 2013 we are hoping to have some preliminary findings to present to the community.



Neurodegenerative Disorders Research Pty Ltd

185 York Street
Subiaco WA 6008

Ph: 6380 2255
Fax: 6380 2055

enquiries@ndr.org.au